Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Rosiglitazone doubles heart failure risk

By Lilian Anekwe

Rosiglitazone does not increase the risk of death from cardiovascular disease, but does double the risk of heart failure, a new analysis shows.

The findings of the RECORD study found 61 patients given rosiglitazone as a second-line drug suffered heart failure causing hospitalisation or death, compared with 29 people on a combination of metformin and sulfonylurea. There were no significant differences in any other cardiovascular endpoint.

Treatment with rosiglitazone also increased the risk of fracture by more than half, by 57%, with the increased risk of fractures much higher in women – at 82% – then the 23% seen in men.

Lead researcher Dr Philip Home, chair of the RECORD steering committee and a professor of diabetes medicine at Newcastle university said: 'Rosiglitazone carries no increased risk of overall cardiovascular death or hospitalisation compared to most commonly used diabetes medicines.'

The study was published in The Lancet and presented at the American Diabetes Association conference in New Orleans last week.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say